Clinical Trial Update: TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations [Phase 3]

View source ↗

Summary

Takeda's TAK-788 is being studied as a first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations in a Phase 3 trial against platinum-based c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAK-788

Snippet

Sponsor: Takeda | Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Status: ACTIVE_NOT_RECRUITING